| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 357.8 | 211.0 |
| Profit before tax | -41.1 | -23.1 |
| Net income | -51.7 | 15.9 |
| EPS (diluted, $ a share) | $-0.62 | $0.20 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +69.6% |
|---|---|
| Operating margin | 7.0% |
10-Q filed with the SEC, NASDAQ: PTCT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
PTC Therapeutics, Inc.: key numbers
- Share price
- $60.97Close, Nov 16
- Market cap
- $5.09B
- Shares outstanding
- 83.54MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from PTC Therapeutics, Inc.
All →PTC Therapeutics Announces $500M Stock Buyback
PTC Therapeutics announced that its Board of Directors has authorized a share repurchase program to buy back up to $500 million of its common stock. The repurchases will be conducted at management's discretion through open-market or privately negotiated transactions based on market conditions.
- Value
- $500M
PTC Therapeutics Financial Results
PTC Therapeutics reported record third-quarter 2026 financial results, with total revenue reaching $358 million, driven by $182 million in sales from the Sephience launch. The company raised its full-year 2026 revenue guidance to a range of $1.29 billion to $1.32 billion and expects to complete its BLA submission for the ST-920 Fabry disease gene therapy in Q4 2026.
“We delivered another strong quarter of record product revenue led by the continued momentum of the Sephience launch, putting us firmly on track to achieve our cash flow breakeven milestone this year. Now at the one-year mark, the launch has been a success by all measures. With a strong patient base, the large global market, and the reports of meaningful treatment benefits, we look forward to continued growth both in the US and internationally.”
Matthew B. Klein, M.D., Chief Executive Officer
PTC Therapeutics Director Michael Schmertzler Sells $149K of Stock
Michael Schmertzler, Director, sold 2,500 shares of PTC Therapeutics, Inc. at $59.52 to $60.14 a share (average $59.61) in 2 transactions, worth $149K in total on Oct 14, 2026. Shares held after the trade: 1,291,594 (-0.0%).
- Value
- $149K
- Shares
- 2,500
- Average price
- $59.61
- Role
- Director
- Holding change
- -0.0%
- Trade date
- Oct 14, 2026
PTC Therapeutics Exec. VP and CLO Mark Elliott Boulding Sells $12.3K of Stock
Mark Elliott Boulding, Exec. VP and CLO, sold 192 shares of PTC Therapeutics, Inc. at $64.26 a share, worth $12.3K in total on Oct 9, 2026. Shares held after the trade: 105,272 (-0.2%).
- Value
- $12.3K
- Shares
- 192
- Price
- $64.26
- Role
- Exec. VP and CLO
- Holding change
- -0.2%
- Trade date
- Oct 9, 2026
PTC Therapeutics Director Michael Schmertzler Sells $155K of Stock
Michael Schmertzler, Director, sold 2,447 shares of PTC Therapeutics, Inc. at $63.38 a share, worth $155K in total on Oct 7, 2026. Shares held after the trade: 1,294,147 (-0.2%).
- Value
- $155K
- Shares
- 2,447
- Price
- $63.38
- Role
- Director
- Holding change
- -0.2%
- Trade date
- Oct 7, 2026
PTC Therapeutics Exec. VP and CLO Mark Elliott Boulding Sells $133K of Stock
Mark Elliott Boulding, Exec. VP and CLO, sold 2,073 shares of PTC Therapeutics, Inc. at $64.03 to $64.16 a share (average $64.06) in 2 transactions, worth $133K in total between Oct 5, 2026 and Oct 6, 2026. Shares held after the trade: 105,272 (-0.4%).
- Value
- $133K
- Shares
- 2,073
- Average price
- $64.06
- Role
- Exec. VP and CLO
- Holding change
- -0.4%
- Trade date
- Oct 5, 2026 to Oct 6, 2026